H.C. Wainwright lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $9 from $20 and keeps a Buy rating on the shares ahead of the Q3 report on November 6. The firm believes Iovance “is squarely in the investor’s penalty box.” It remains positive on the shares but believes the company is in a “show-me” stage.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study
- Iovance Biotherapeutics’ Phase 3 Study: A Potential Game-Changer in Melanoma Treatment
- Iovance Biotherapeutics Advances TIL Therapy in Pediatric Cancer Study
- Iovance Biotherapeutics’ Promising Phase 2 Study on LN-145 for Lung Cancer
- Iovance Biotherapeutics’ Innovative Cancer Study: A Potential Game-Changer?